Literature DB >> 14508201

A role for cardiac mast cells in the pathogenesis of hypertensive heart disease.

Naotaka Shiota1, Jaana Rysä, Petri T Kovanen, Heikki Ruskoaho, Jorma O Kokkonen, Ken A Lindstedt.   

Abstract

OBJECTIVE: Cardiac mast cells participate in myocardial dysfunction, but the mechanisms are presently unknown.
DESIGN: By examining spontaneously hypertensive rats (SHRs) during their entire lifespan, we attempted to define the role of mast cells in the induction of cardiac hypertrophy and transition to heart failure. METHODS AND
RESULTS: By contrast to normotensive littermates, hearts of newborn SHRs already contained mast cells. In the prehypertensive (2-week-old) SHRs, the increased expression of c-kit and soluble stem cell factor correlated with an increased number of cardiac mast cells. The mast cells contained tumour necrosis factor-alpha which, together with nuclear factor kappa-B (NF-kappaB) and interleukin (IL)-6, was significantly induced in the prehypertensive SHRs. Stimulation of cardiac mast cells with compound 48/80 in an ex-vivo Langendorff heart perfusion system resulted in increased expression of nuclear factor Kappa-B (NF-kappaB) (four-fold) and IL-6 (nine-fold) mRNA in the left ventricles of adult rat hearts. In the presence of an inhibitor of mast cell degranulation, disodium cromoglycate, the induced expression of NF-kappaB and IL-6 was inhibited. In the late hypertensive stage, the hearts of SHRs with advanced cardiac hypertrophy (12-month-old) and heart failure (20-month-old) had significantly increased levels of transforming growth factor (TGF)-beta1 and basic fibroblast growth factor (bFGF), and displayed increased myocardial fibrosis. Activated mast cells were a major source of TGF-beta1 and bFGF, and localized to areas of myocardial fibrosis.
CONCLUSIONS: By synthesizing and secreting prohypertrophic cytokines and profibrotic growth factors, cardiac mast cells participate in the induction of cardiac hypertrophy and cardiac fibrosis, which are the key steps in the transition to heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508201     DOI: 10.1097/00004872-200310000-00022

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  40 in total

Review 1.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

Review 2.  Mast cells and metabolic syndrome.

Authors:  Jie Zhang; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2010-12-23

Review 3.  Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase.

Authors:  Joseph S Janicki; Francis G Spinale; Scott P Levick
Journal:  Pflugers Arch       Date:  2013-02-16       Impact factor: 3.657

4.  CD117-positive cells of the heart: progenitor cells or mast cells?

Authors:  Yan Zhou; Peng Pan; Lu Yao; Meng Su; Ping He; Na Niu; Michael A McNutt; Jiang Gu
Journal:  J Histochem Cytochem       Date:  2009-12-21       Impact factor: 2.479

Review 5.  Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

Authors:  Sarfaraz Ahmad; Carlos M Ferrario
Journal:  Expert Opin Ther Pat       Date:  2018-10-10       Impact factor: 6.674

6.  Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.

Authors:  Jaime S Horton; Cadie L Buckley; Alexander J Stokes
Journal:  Channels (Austin)       Date:  2012-12-06       Impact factor: 2.581

7.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

Authors:  Yun-He Liu; Martin D'Ambrosio; Tang-dong Liao; Hongmei Peng; Nour-Eddine Rhaleb; Umesh Sharma; Sabine André; Hans-J Gabius; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-19       Impact factor: 4.733

Review 8.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

9.  Reduction of rat cardiac hypertrophy by osthol is related to regulation of cardiac oxidative stress and lipid metabolism.

Authors:  Feng Zhou; Wen Zhong; Jie Xue; Zhen-lun Gu; Mei-lin Xie
Journal:  Lipids       Date:  2012-08-24       Impact factor: 1.880

10.  Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats.

Authors:  Scott P Levick; Jason D Gardner; Merrilee Holland; Martin Hauer-Jensen; Joseph S Janicki; Gregory L Brower
Journal:  J Mol Cell Cardiol       Date:  2008-05-02       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.